Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01575873 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 795
- Enrollment target
NCT01575873 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 795 participants.
The verdict
NCT01575873, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 795 participants
- Enrollment target
Study Summary
This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
Interventions
- DRUG Denosumab
- DRUG Placebo for risendronate
- DRUG Risendronate
- DRUG Placebo for denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 795 participants |
| Start Date | 2012-03-28 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01575873
The ClinicalTrials.gov registry entry for NCT01575873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 795 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Denosumab is the first listed.
NCT01575873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01575873 about?
NCT01575873 is a clinical study titled "Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids". This is a 2-year study to evaluate the effect of denosumab versus risedronate in adults with glucocorticoid-induced osteoporosis.
What is the current status of trial NCT01575873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 795 participants. The study started on 2012-03-28. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT01575873?
The interventions under investigation include: Denosumab (DRUG), Placebo for risendronate (DRUG), Risendronate (DRUG), Placebo for denosumab (DRUG).
Who is sponsoring clinical trial NCT01575873?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.